Standard Radiotherapy Dose for Indolent Lymphoma Prevails in FoRT Trial
Investigators assessed outcomes following a radiotherapy dose of 4 Gy in 2 fractions vs 24 Gy in 12 fractions in patients with follicular lymphoma or marginal zone lymphoma.
Hematologic Cancers
Ruxolitinib Gets Priority Review for Chronic Graft-vs-Host Disease
The sNDA submission is based on data from the multicenter, randomized, open-label phase 3 REACH3 study.
Study Confirms Stem Cell Transplantation Increases Mortality Risk From COVID-19
Patients who have undergone either autologous or allogeneic hematopoietic stem cell transplantation (HSCT) are at high risk for mortality in the event of a COVID-19 diagnosis.
Measurable Residual Disease Is Prognostic Factor Before Transplantation in First and Second Remission of Ph+ ALL
A team of investigators evaluated the effect of measurable residual disease at time of allogeneic hematopoietic cell transplantation in patients with ALL undergoing transplantation during either first or second complete remission.
Survey Reveals Varied Treatment of VTE in Pediatric Acute Lymphocytic Leukemia
A team of researchers identified a lack of standardized practices for treating venous thromboembolism among pediatric patients with acute lymphocytic leukemia.
Clinical Trial: Investigators Testing E-selectin Antagonist/Chemotherapy Combination in R/R AML
Uproleselan will be evaluated in combination with chemotherapy in a phase 3 trial of patients with relapsed or refractory acute myeloid leukemia (AML).
Clinical Trial: Epcoritamab to Be Evaluated in R/R DLBCL
Investigators of a phase 3 trial will compare epcoritamab with investigator’s choice of chemotherapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Clinical Trial: Investigational BTK Inhibitor Undergoes Investigation in CLL, B-Cell Lymphoma
Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.
Clinical Trial: LOXO-305 Faces Off Against FDA-Approved Covalent BTK Inhibitors
Loxo Oncology is preparing to initiate the global, randomized, BRUIN MCL-321 superiority study in patients with Bruton tyrosine kinase inhibitor-naïve disease.
Rituximab Well-Tolerated in Children, but Associated With High Risk for Infection
Although rituximab is well-tolerated by children, infections are common and time to recovery of B lymphocytes, prolonged.
-
Loading...
-
Loading...
